1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
-
  1. Products
  2. Solutions
  3. Insights+
  4. News & content
  5. About
  1. Launch

Roca Therapeutics

Have updates for this profile?  Please contribute data

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.

Year established

2021

Location

France

Primary Industry

Biotechnology

About

Based in France and founded in 2021, Roca Therapeutics is a biotech startup specializing in the discovery and development of small molecules addressing severe life-threatening disorders. Maeva Dufies (CEO and CSO), Zaki Sellam, Gilles Pagès, Rachid Benhida, and Cyril Ronco are the co-founders of the company. In September 2022, Roca Therapeutics raised Seed funding from 3B Future Health Fund and SATT Sud-Est. The company provides its products, including RCT001 (Metastatic Uveal Melanoma), which is the treatment for a primary and metastatic form of uveal melanoma; and RCT002 (Neovascular Complications), which is the treatment and prevention of neovascular complications after proton therapy, such as glaucoma and retinopathy. The firm's partners include Ircan, Inserm, I-Lab, Bpifrance, Cnrs, and more. The organization plans to use the September 2022 funding to develop its lead clinical candidate RCT001 (Metastatic Uveal Melanoma) until IND/CTA readiness in 2023 and to further expand the company’s portfolio of assets with the nomination of a second clinical candidate for Neovascular Glaucoma associated with uveal melanoma.
Current Investors
3B Future Health Fund

Request a demo to show more

Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.roca-therapeutics.org
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.